BFC Planning’s Spyre Therapeutics SYRE Stock Holding History
Bought
Maintained
Sold
Other funds holding SYRE
BFC Planning's SYRE Position: Q3 2026 in Review
BFC Planning opened a new position in Spyre Therapeutics (SYRE) in Q3 2026: 37 shares worth $3.29K. The stake represents ﹤0.01% of the portfolio and ranks #2848 among its holdings.
193 funds tracked by Wall St. Rank hold SYRE as of Q3 2026.
- BFC Planning held 37 shares of Spyre Therapeutics worth $3.29K as of Q3 2026.
- Spyre Therapeutics was a new BFC Planning position in Q3 2026.
- Spyre Therapeutics made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #2848 holding.
- 193 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2026.
Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.